Merck KGaA (FRA:MRK) has been assigned a €95.00 ($117.28) price objective by research analysts at JPMorgan Chase & Co. in a research note issued on Monday, February 19th. The brokerage presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.’s target price points to a potential upside of 22.27% from the stock’s current price.
MRK has been the subject of a number of other research reports. Oddo Bhf set a €125.00 ($154.32) price objective on Merck KGaA and gave the company a “buy” rating in a report on Friday, November 10th. UBS Group set a €120.00 ($148.15) price objective on Merck KGaA and gave the company a “buy” rating in a report on Monday, January 8th. Nord/LB reiterated a “neutral” rating on shares of Merck KGaA in a report on Wednesday, December 27th. Kepler Capital Markets set a €115.00 ($141.98) price objective on Merck KGaA and gave the company a “buy” rating in a report on Monday, November 6th. Finally, Deutsche Bank set a €99.00 ($122.22) price objective on Merck KGaA and gave the company a “neutral” rating in a report on Friday, November 10th. Twelve analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of €101.77 ($125.65).
Merck KGaA (FRA MRK) traded down €0.64 ($0.79) during midday trading on Monday, reaching €77.70 ($95.93). The company had a trading volume of 606,091 shares. The company has a market capitalization of $10,090.00 and a P/E ratio of 12.99. Merck KGaA has a fifty-two week low of €76.60 ($94.57) and a fifty-two week high of €115.00 ($141.98).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.